Latest Posts
About This Stock
More About This Stock
Read
Read
Read
Read
Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion
Article By:
ChinaBio® Today
Sunday, January 7, 2024 7:20 AM EDT
Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China) for AVZO-021 to Avenzo Therapeutics.
Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal
Article By:
ChinaBio® Today
Saturday, November 11, 2023 12:40 PM EDT
Eccogene, a Shanghai-Boston biotech, out-licensed global rights (ex-China) for its novel small molecule GLP-1 agonist to AstraZeneca in a $2 billion blockbuster deal. Eccogene will receive $185 million upfront and up to $1.8 billion in milestones.
Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal
Article By:
ChinaBio® Today
Saturday, September 2, 2023 1:59 PM EDT
Shanghai GenFleet Technologies partnered three preclinical small-molecule candidates for RAS pathway-driven cancers to Verastem Oncology in a deal that could be worth up to $625.5 million. GenFleet will receive an initial payment of $11.5 million.
Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership
Article By:
ChinaBio® Today
Saturday, August 12, 2023 2:39 PM EDT
BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies raised $100 million in a private placement.